


Figure 1


A
HCQ.4, Untreated
HCQ.4, Anti-CD3
Counts
Anti-A1M
B
HCQ.4, Ethanol
HCQ.4, DMSO
Propidium Iodide (PI)
Anti-A1M
C
70Z/3, 3-CPA
Counts
A1M-Biotin

D


K562, Heme
10 µM

E


HCQ.4, Untreated
HCQ.4, Anti-CD3
Binding of 125I-A1M (Cpm)
8000
6000
4000
2000
0
***
1
2
3
4
5




A
0h
1h
2h
4h
8h
16h
Propidium Iodide (PI)
A1M-FITC
B
7AAD negative
7AAD positive
A1M-Biotin
Annexin

Figure 2







Figure 3

Figure 4


A
Inhibition of 125I-A1M
(% of control)
100
75
50
***
***
A1M (µg) - 1.6 8.0 40 -
AGP (µg) - - - - 40
B
1236
1048
480
242
CI/CIII
CI
Coomassie
Anti-CI
NDUFV1
Anti-A1M
Anti-CIII
Core I
C
170
70
55
40
25
CI/CIII
CIII
SM IP

Supplementary Figure 1




Figure 5




Figure 6





Figure 7

Figure 8


A
ATP production (% of Control)
100
50
0
*
*
Heme (μM) - 1.0 5.0 20 1.0 5.0 10
A1M (μM) - - - - 10 10 10
B
ATP production (% of Control)
100
95
90
*
*
H2O2 (μM) - 20 100 250 20 100 250
A1M (μM) - - - - 10 10 10

120912 A1M Sequence list_ST25.txt
SEQUENCE LISTING

<110> Åkerstrm, Bo et al

<120> Alpha 1- microgobuin fr use in the treatment of mitochondria-related diseases
1-microglobulin

<130> P81204108DK00

<160> 5

<170> PatentIn version 3.5

<210> 1
<211> 183
<212> PRT
<213> Homo sapiens

<400> 1

Gly Pro Val Pro Thr Pro Pro Asp Asn Ile Gln Val Gln Glu Asn Phe
1 5 10 15

Asn Ile Ser Arg Ile Tyr Gly Lys Trp Tyr Asn Leu Ala Ile Gly Ser
20 25 30

Thr Cys Pro Trp Leu Lys Lys Ile Met Asp Arg Met Thr Val Ser Thr
35 40 45

Leu Val Leu Gly Glu Gly Ala Thr Glu Ala Glu Ile Ser Met Thr Ser
50 55 60

Thr Arg Trp Arg Lys Gly Val Cys Glu Glu Thr Ser Gly Ala Tyr Glu
65 70 75 80

Lys Thr Asp Thr Asp Gly Lys Phe Leu Tyr His Lys Ser Lys Trp Asn
85 90 95

Ile Thr Met Glu Ser Tyr Val Val His Thr Asn Tyr Asp Glu Tyr Ala
100 105 110

Ile Phe Leu Thr Lys Lys Phe Ser Arg His His Gly Pro Thr Ile Thr
115 120 125

Ala Lys Leu Tyr Gly Arg Ala Pro Gln Leu Arg Glu Thr Leu Leu Gln
130 135 140

Asp Phe Arg Val Val Ala Gln Gly Val Gly Ile Pro Glu Asp Ser Ile
145 150 155 160

Phe Thr Met Ala Asp Arg Gly Glu Cys Val Pro Gly Glu Gln Glu Pro
165 170 175

Glu Pro Ile Leu Ile Pro Arg
180

Figure 9

<210> 2
<211> 201
<212> PRT
<213> Homo sapiens

<400> 2

Met His His His His His His His His Gly Gly Gly Gly Gly Ile Glu
1 5 10 15

Gly Arg Gly Pro Val Pro Thr Pro Pro Asp Asn Ile Gln Val Gln Glu
20 25 30

Asn Phe Asn Ile Ser Arg Ile Tyr Gly Lys Trp Tyr Asn Leu Ala Ile
35 40 45

Gly Ser Thr Cys Pro Trp Leu Lys Lys Ile Met Asp Arg Met Thr Val
50 55 60

Ser Thr Leu Val Leu Gly Glu Gly Ala Thr Glu Ala Glu Ile Ser Met
65 70 75 80

Thr Ser Thr Arg Trp Arg Lys Gly Val Cys Glu Glu Thr Ser Gly Ala
85 90 95

Tyr Glu Lys Thr Asp Thr Asp Gly Lys Phe Leu Tyr His Lys Ser Lys
100 105 110

Trp Asn Ile Thr Met Glu Ser Tyr Val Val His Thr Asn Tyr Asp Glu
115 120 125

Tyr Ala Ile Phe Leu Thr Lys Lys Phe Ser Arg His His Gly Pro Thr
130 135 140

Ile Thr Ala Lys Leu Tyr Gly Arg Ala Pro Gln Leu Arg Glu Thr Leu
145 150 155 160

Leu Gln Asp Phe Arg Val Val Ala Gln Gly Val Gly Ile Pro Glu Asp
165 170 175

Ser Ile Phe Thr Met Ala Asp Arg Gly Glu Cys Val Pro Gly Glu Gln
180 185 190

Glu Pro Glu Pro Ile Leu Ile Pro Arg
195 200

<210> 3
<211> 549
<212> DNA
<213> Homo sapiens

<400> 3
ggccctgtgc caacgccgcc cgacaacatc caagtgcagg aaaacttcaa tatctctcgg 60

atctatggga agtggtacaa cctggccatc ggttccacct gcccctggct gaagaagatc 120

atggacagga tgacagtgag cacgctggtg ctgggagagg gcgctacaga ggcggagatc 180

agcatgacca gcactcgttg gcggaaaggt gtctgtgagg agacgtctgg agcttatgag 240

aaaacagata ctgatgggag gtttctctat cacaaatcca aatggaacat aaccatggag 300

tcctatgtgg tccacaccac ctatgatgag tatgccattt ttctgaccaa gaaattcagc 360

cgccatcatg gacccaccat tactgccaag ctctacgggc gggcgccgca gctgagggaa 420

actctcctgc aggacttcag agtggttgcc cagggtgtgg gcatccctga ggactccatc 480

ttcaccatgg ctgaccgagg tgaatgtgtc cctggggagc aggaaccaga gcccatctta 540

atcccgaga 549

<210> 4
<211> 603
<212> DNA
<213> Homo sapiens

<400> 4
atgcatcacc atcaccatca ccatcacggt ggaggagggg gtatcgaggg ccgcggccct 60

gtgccaacgc cgcccgacaa catccaagtg caggaaaact tcaatatctc tcggatctat 120

gggaagtggt acaacctggc catcggttcc acctgcccct ggctgaagaa gatcatggac 180

aggatgacag tgagcacgct ggtgctggga gagggcgcta cagaggcgga gatcagcatg 240

accagcactc gttggcggaa aggtgtctgt gaggagacgt ctggagctta tgagaaaaca 300

gatactgatg ggaggtttct ctatcacaaa tccaaatgga acataaccat ggagtcctat 360

gtggtccaca ccacctatga tgagtatgcc atttttctga ccaagaaatt cagccgccat 420

catggaccca ccattactgc caagctctac gggcgggcgc cgcagctgag ggaaactctc 480

ctgcaggact tcagagtggt tgcccagggt gtgggcatcc ctgaggactc catcttcacc 540

atggctgacc gaggtgaatg tgtccctggg gagcaggaac cagagcccat cttaatcccg 600


aga 603

<210> 5
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> for silencing expression of alpha-1-microglobulin

<400> 5
ccuauguggu ccacaccaa 19

Figure 10


A
B
ΔΔt
1,0
0,5
0,0
-0,5
-1,0
-1,5
-2,0
-2,5
0,7
0,6
0,5
0,4
0,3
0,2
0,1
0,0
2h
48h
12S mito rRNA
A1M
HO-1
SOD